---
document_datetime: 2025-12-02 05:57:18
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/lumoxiti.html
document_name: lumoxiti.html
version: success
processing_time: 0.1046418
conversion_datetime: 2025-12-27 14:07:15.504415
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Lumoxiti

[RSS](/en/individual-human-medicine.xml/67405)

##### Withdrawn

This medicine's authorisation has been withdrawn

moxetumomab pasudotox Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Lumoxiti](#news-on)
- [More information on Lumoxiti](#more-information-on-lumoxiti-920)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 23 July 2021 the European Commission withdrew the marketing authorisation for Lumoxiti (moxetumomab pasudotox) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, AstraZeneca AB, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Lumoxiti was granted marketing authorisation in the EU on 8 February 2021 for treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL) after receiving at least two prior systemic therapies. The marketing authorisation was initially valid for a 5-year period. The product had not been marketed in the EU.

The European Public Assessment Report (EPAR) for Lumoxiti is updated to indicate that the marketing authorisation is no longer valid.

Lumoxiti : EPAR - Medicine overview

Reference Number: EMA/691967/2020

English (EN) (724.73 KB - PDF)

**First published:** 09/03/2021

**Last updated:** 11/08/2021

[View](/en/documents/overview/lumoxiti-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-531)

български (BG) (815.81 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/bg/documents/overview/lumoxiti-epar-medicine-overview_bg.pdf)

español (ES) (722.86 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/es/documents/overview/lumoxiti-epar-medicine-overview_es.pdf)

čeština (CS) (793.79 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/cs/documents/overview/lumoxiti-epar-medicine-overview_cs.pdf)

dansk (DA) (721.03 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/da/documents/overview/lumoxiti-epar-medicine-overview_da.pdf)

Deutsch (DE) (1.29 MB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/de/documents/overview/lumoxiti-epar-medicine-overview_de.pdf)

eesti keel (ET) (715.6 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/et/documents/overview/lumoxiti-epar-medicine-overview_et.pdf)

ελληνικά (EL) (819.77 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/el/documents/overview/lumoxiti-epar-medicine-overview_el.pdf)

français (FR) (725.87 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/fr/documents/overview/lumoxiti-epar-medicine-overview_fr.pdf)

hrvatski (HR) (746.79 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/hr/documents/overview/lumoxiti-epar-medicine-overview_hr.pdf)

italiano (IT) (1.28 MB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/it/documents/overview/lumoxiti-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (805.12 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/lv/documents/overview/lumoxiti-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (746.92 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/lt/documents/overview/lumoxiti-epar-medicine-overview_lt.pdf)

magyar (HU) (793.41 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/hu/documents/overview/lumoxiti-epar-medicine-overview_hu.pdf)

Malti (MT) (797.91 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/mt/documents/overview/lumoxiti-epar-medicine-overview_mt.pdf)

Nederlands (NL) (721.98 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/nl/documents/overview/lumoxiti-epar-medicine-overview_nl.pdf)

polski (PL) (795.38 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/pl/documents/overview/lumoxiti-epar-medicine-overview_pl.pdf)

português (PT) (723.86 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/pt/documents/overview/lumoxiti-epar-medicine-overview_pt.pdf)

română (RO) (746.19 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/ro/documents/overview/lumoxiti-epar-medicine-overview_ro.pdf)

slovenčina (SK) (794 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/sk/documents/overview/lumoxiti-epar-medicine-overview_sk.pdf)

slovenščina (SL) (793.45 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/sl/documents/overview/lumoxiti-epar-medicine-overview_sl.pdf)

Suomi (FI) (719.9 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/fi/documents/overview/lumoxiti-epar-medicine-overview_fi.pdf)

svenska (SV) (720.85 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/sv/documents/overview/lumoxiti-epar-medicine-overview_sv.pdf)

Lumoxiti : EPAR - Risk-management-plan summary

English (EN) (754.84 KB - PDF)

**First published:** 09/03/2021

**Last updated:** 11/08/2021

[View](/en/documents/rmp-summary/lumoxiti-epar-risk-management-plan-summary_en.pdf)

## Product information

Lumoxiti : EPAR - Product information

English (EN) (1016.76 KB - PDF)

**First published:** 09/03/2021

**Last updated:** 11/08/2021

[View](/en/documents/product-information/lumoxiti-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-450)

български (BG) (1.82 MB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/bg/documents/product-information/lumoxiti-epar-product-information_bg.pdf)

español (ES) (959.63 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/es/documents/product-information/lumoxiti-epar-product-information_es.pdf)

čeština (CS) (1.5 MB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/cs/documents/product-information/lumoxiti-epar-product-information_cs.pdf)

dansk (DA) (973.12 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/da/documents/product-information/lumoxiti-epar-product-information_da.pdf)

Deutsch (DE) (1011.13 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/de/documents/product-information/lumoxiti-epar-product-information_de.pdf)

eesti keel (ET) (951 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/et/documents/product-information/lumoxiti-epar-product-information_et.pdf)

ελληνικά (EL) (1.91 MB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/el/documents/product-information/lumoxiti-epar-product-information_el.pdf)

français (FR) (1 MB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/fr/documents/product-information/lumoxiti-epar-product-information_fr.pdf)

hrvatski (HR) (798.78 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/hr/documents/product-information/lumoxiti-epar-product-information_hr.pdf)

íslenska (IS) (975.57 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/is/documents/product-information/lumoxiti-epar-product-information_is.pdf)

italiano (IT) (952.21 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/it/documents/product-information/lumoxiti-epar-product-information_it.pdf)

latviešu valoda (LV) (1.55 MB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/lv/documents/product-information/lumoxiti-epar-product-information_lv.pdf)

lietuvių kalba (LT) (836.52 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/lt/documents/product-information/lumoxiti-epar-product-information_lt.pdf)

magyar (HU) (1.53 MB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/hu/documents/product-information/lumoxiti-epar-product-information_hu.pdf)

Malti (MT) (894.3 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/mt/documents/product-information/lumoxiti-epar-product-information_mt.pdf)

Nederlands (NL) (966.08 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/nl/documents/product-information/lumoxiti-epar-product-information_nl.pdf)

norsk (NO) (977.84 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/no/documents/product-information/lumoxiti-epar-product-information_no.pdf)

polski (PL) (1.56 MB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/pl/documents/product-information/lumoxiti-epar-product-information_pl.pdf)

português (PT) (1.01 MB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/pt/documents/product-information/lumoxiti-epar-product-information_pt.pdf)

română (RO) (818.55 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/ro/documents/product-information/lumoxiti-epar-product-information_ro.pdf)

slovenčina (SK) (1.52 MB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/sk/documents/product-information/lumoxiti-epar-product-information_sk.pdf)

slovenščina (SL) (1.47 MB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/sl/documents/product-information/lumoxiti-epar-product-information_sl.pdf)

Suomi (FI) (813.39 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/fi/documents/product-information/lumoxiti-epar-product-information_fi.pdf)

svenska (SV) (971.85 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/sv/documents/product-information/lumoxiti-epar-product-information_sv.pdf)

23/07/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Lumoxiti : EPAR - All authorised presentations

English (EN) (599.6 KB - PDF)

**First published:** 09/03/2021

**Last updated:** 11/08/2021

[View](/en/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-265)

български (BG) (1.18 MB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/bg/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_bg.pdf)

español (ES) (602.88 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/es/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_es.pdf)

čeština (CS) (616.51 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/cs/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (624.71 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/da/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (602.32 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/de/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (601.63 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/et/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (621.92 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/el/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_el.pdf)

français (FR) (599.55 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/fr/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (1.14 MB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/hr/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (618.09 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/is/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_is.pdf)

italiano (IT) (597.58 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/it/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (612.93 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/lv/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (594.59 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/lt/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (615.51 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/hu/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (620.58 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/mt/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (598.96 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/nl/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (627.26 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/no/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_no.pdf)

polski (PL) (619.32 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/pl/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_pl.pdf)

português (PT) (595.43 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/pt/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_pt.pdf)

română (RO) (603.25 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/ro/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (616.54 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/sk/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (615.72 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/sl/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (621.52 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/fi/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (625.74 KB - PDF)

**First published:**

09/03/2021

**Last updated:**

11/08/2021

[View](/sv/documents/all-authorised-presentations/lumoxiti-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Lumoxiti Active substance moxetumomab pasudotox International non-proprietary name (INN) or common name moxetumomab pasudotox Therapeutic area (MeSH) Leukemia, Hairy Cell Anatomical therapeutic chemical (ATC) code L01X

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (PNA).

## Authorisation details

EMA product number EMEA/H/C/005322 Marketing authorisation holder

AstraZeneca AB

SE-151 85 Sodertalje

Opinion adopted 10/12/2020 Marketing authorisation issued 08/02/2021

## Assessment history

## Initial marketing authorisation documents

Lumoxiti : Orphan maintenance assessment report

Adopted

Reference Number: EMADOC-1700519818-608352

English (EN) (922.17 KB - PDF)

**First published:** 09/03/2021

**Last updated:** 11/08/2021

[View](/en/documents/orphan-maintenance-report/lumoxiti-orphan-maintenance-assessment-report_en.pdf)

Lumoxiti : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/36661/2021

English (EN) (6.14 MB - PDF)

**First published:** 09/03/2021

**Last updated:** 11/08/2021

[View](/en/documents/assessment-report/lumoxiti-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Lumoxiti

Adopted

Reference Number: EMA/CHMP/652159/2020

English (EN) (737.82 KB - PDF)

**First published:** 11/12/2020

**Last updated:** 11/08/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-lumoxiti_en.pdf)

#### News on Lumoxiti

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020) 11/12/2020

#### More information on Lumoxiti

This product was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-08-592) on 5 December 2008. Lumoxiti was withdrawn from the Community register of orphan medicinal products by the European Commission in July 2021 at the time of the withdrawal of the marketing authorisation.

**This page was last updated on** 11/08/2021

## Share this page

[Back to top](#main-content)